Drug Profile
Research programme: skin disorder topical therapeutics - Foamix
Alternative Names: Benzoyl peroxide foam - Foamix; Betamethasone dipropionate foam - Foamix; Calcipotriene foam - Foamix; Calcipotriol foam - Foamix; Ciclopirox foam - Foamix; Ciclopiroxolamine foam - Foamix; Clobetasol propionate foam - Foamix; Lactic acid/urea foam - Foamix; Salicylic acid foam - Foamix; Triamcinolone acetonide foam - Foamix; U-LAC foam; UFoam; Urea foam - Foamix; Urea/lactic acid foam - FoamixLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Foamix
- Developer Foamix; Therapeutics Incorporated
- Class Benzoic acids; Corticosteroids; Cyclohexanes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Hydroxy acids; Indenes; Lactates; Oxidants; Pregnadienes; Pyridones; Salicylates; Small molecules; Urea compounds; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists; Cytokine inhibitors; Glucocorticoid receptor agonists; Matrix metalloproteinase inhibitors; Mitosis inhibitors; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acne; Atopic dermatitis; Dermatomycoses; Dry skin; Hyperhidrosis; Psoriasis; Seborrhoeic dermatitis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Acne in Israel (Topical, Foam)
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 31 Dec 2018 FCD 105 is in preclinical trials for Acne in Israel